Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: BSI-201

First Posted Date: 2009-12-16

Last Posted Date: 2016-03-17

Lead Sponsor: Sanofi

Target Recruit Count: 43

Registration Number: NCT01033292

Locations: 🇺🇸
Massachusetts Ceneral Hospital, Boston, Massachusetts, United States

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: BSI-201

First Posted Date: 2009-12-16

Last Posted Date: 2016-03-17

Lead Sponsor: Sanofi

Target Recruit Count: 41

Registration Number: NCT01033123

Locations: 🇺🇸
Massachusetts Ceneral Hospital, Boston, Massachusetts, United States

Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age

Phase 4

Completed

Conditions: Diphtheria
Tetanus
Pertussis
Poliomyelitis

Interventions: Biological: DTacP-IPV combined vaccine (TETRAXIM™)

First Posted Date: 2009-12-14

Last Posted Date: 2011-10-05

Lead Sponsor: Sanofi

Target Recruit Count: 123

Registration Number: NCT01031303

Dronedarone Pattern of Use in Patients Scheduled for Elective Cardioversion (ELECTRA)

Phase 4

Terminated

Conditions: Atrial Fibrillation

Interventions: Drug: Dronedarone
Drug: Placebo (for dronedarone)

First Posted Date: 2009-12-04

Last Posted Date: 2014-08-06

Lead Sponsor: Sanofi

Target Recruit Count: 292

Registration Number: NCT01026090

Locations: 🇨🇦
Investigational Site Number 1240002, Ste-Foy, Canada
🇨🇦
Investigational Site Number 1240018, Newmarket, Canada
🇨🇦
Investigational Site Number 1240012, Niagara Falls, Canada

and more 40 locations

Artesunate Plus Amodiaquine in Malaria in Cote d'Ivoire

Phase 4

Completed

Conditions: Malaria

Interventions: Drug: Artesunate + Amodiaquine

First Posted Date: 2009-12-02

Last Posted Date: 2015-02-23

Lead Sponsor: Sanofi

Target Recruit Count: 580

Registration Number: NCT01023399

Locations: 🇨🇮
Investigational Site Number 1, Agboville district, Côte D'Ivoire

Efficacy and Safety Assessment of ZOlpidem (Stilnox CR) in Patients With Chronic insomNIA

Phase 4

Completed

Conditions: Sleep Disorders

Interventions: Drug: ZOLPIDEM SL800750

First Posted Date: 2009-12-02

Last Posted Date: 2010-10-05

Lead Sponsor: Sanofi

Target Recruit Count: 135

Registration Number: NCT01024192

Locations: 🇲🇽
Sanofi-Aventis Administrative Office, Col. Coyoacan, Mexico

Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Cisplatin in Patients With Solid Tumors

Phase 1

Completed

Conditions: Neoplasms, Malignant

Interventions: Drug: ombrabulin (AVE8062)
Drug: cisplatin

First Posted Date: 2009-11-26

Last Posted Date: 2011-06-13

Lead Sponsor: Sanofi

Target Recruit Count: 12

Registration Number: NCT01021150

Locations: 🇯🇵
Sanofi-Aventis Administrative Office, Tokyo, Japan

Self Titration With Apidra to Reach Target Study (START)

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: insulin glargine
Drug: Apidra (insulin glulisine)

First Posted Date: 2009-11-13

Last Posted Date: 2012-03-21

Lead Sponsor: Sanofi

Target Recruit Count: 493

Registration Number: NCT01013571

Locations: 🇨🇦
Sanofi-Aventis Administrative Office, Laval, Canada

Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma

Phase 2

Completed

Conditions: Endometrial Neoplasms
Endometrial Cancer

Interventions: Drug: XL147 (SAR245408)

First Posted Date: 2009-11-13

Last Posted Date: 2016-06-03

Lead Sponsor: Sanofi

Target Recruit Count: 67

Registration Number: NCT01013324

Locations: 🇺🇸
Investigational Site Number 1434, Oklahoma City, Oklahoma, United States
🇺🇸
Investigational Site Number 1134, Philadelphia, Pennsylvania, United States
🇧🇪
Investigational Site Number 3218, Wilrijk, Belgium

and more 10 locations

START: Swiss Taxotere Alopecia Prevention Trial

Not Applicable

Completed

Conditions: Neoplasms
Alopecia

Interventions: Device: Paxman Cooling Machine
Device: Cold Caps

First Posted Date: 2009-11-06

Last Posted Date: 2012-01-23

Lead Sponsor: Sanofi

Target Recruit Count: 239

Registration Number: NCT01008774

Locations: 🇨🇭
Sanofi-Aventis Administrative Office, Geneva, Switzerland

Home Terms & Conditions Privacy Policy